ADAG

Adagene Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Current Price

—

Profile

Valuation (TTM)

Market Cap—

P/E—

EV—

P/B—

Shares Out—

P/Sales—

Revenue—

EV/EBITDA—

Adagene Inc (ADAG) Financial Statements

ADAG Financial Data

EBITDA—

Revenue (TTM)—

Gross Profit (TTM)—

Gross Margin—

Operating Margin—

ROE—

ROA—

Debt/Equity—

Current Ratio—

FCF—

FCF Yield—

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA—

200-Day MA—

Shares Outstanding—

ADAG Computed Insights

FCF—

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

ADAG Financial Statements & Data

Adagene Inc (ADAG) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Adagene Inc's financial performance and position as a Healthcare company.

Weighted average cost of capital (WACC) is 10.00%.

GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Adagene Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.